ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

modzatinib

Also written as “Modzatinib” and “ATI-2138”.

Its studies are mostly in Lichen Planus · Dermatitis, Atopic, led by Aclaris Therapeutics.

Furthest: phase 2, since Sep 3, 20242 company-led studies, 1 open or runningNext primary completion: Mar 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Aclaris Therapeutics21 open or runningphase 2since Sep 3, 2024Sep 3, 2024Mar 2029phase 2 · NCT07935590

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Sep 3, 2024First study: phase 2 study in Dermatitis, AtopicFirst studyNCT06585202 · 14 enrolled · United States
  2. Jul 10, 2025Named modzatinibINNProposed as its International Nonproprietary Name in WHO's List 133 · before, ATI-2138
  3. Nov 9, 2026Phase 2 study in Lichen PlanusNCT07935590 · 102 planned · United States

Ahead

  1. Mar 2029Primary completion: phase 2 study in Lichen PlanusNCT07935590

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07935590Lichen Planus · United States2RecruitingMar 2029102
NCT06585202Dermatitis, Atopic · United States2CompletedMar 13, 202514

How it is read

Names in the registry

  • “Modzatinib”, 1 entry
  • “ATI-2138”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.